Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on North Carolina Wellness News.
Press releases published on June 25, 2025

ORYZON to Host Virtual KOL Event on July 9, 2025
MADRID and CAMBRIDGE, Mass., June 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that it will host a virtual KOL event on …

Grace Therapeutics Announces Submission of New Drug Application to U.S. Food and Drug Administration for GTx-104
Submission Seeks Approval of GTx-104 in the Treatment of Patients with aneurysmal Subarachnoid Hemorrhage (aSAH) Comprehensive Data Package Includes Positive Results from Phase 3 STRIVE-ON Safety Trial of GTx-104 Submission Has the Potential to Trigger …

Soleno Therapeutics Highlights New Data on VYKAT(TM) XR at the 2025 United in Hope: International Prader-Willi Syndrome Conference
REDWOOD CITY, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today highlighted new data on VYKATTM XR (diazoxide …

Corvus Pharmaceuticals Announces Partner Angel Pharmaceuticals Received IND Approval for a Phase 1b/2 Clinical Trial of Soquelitinib in China for the Treatment of Atopic Dermatitis
SOUTH SAN FRANCISCO, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced that the IND application submitted by its partner in China, Angel Pharmaceuticals Ltd. ( …

Basecamp Research Announces Malawi Biodiscovery Partnership in Series of New Collaborations Across Three Continents at UK Government Nature Action Event
Partnerships with Malawi, Hungary, and other new partners will rapidly expand BaseData, the largest biological protein database designed specifically for training generative AI foundation models to improve drug discovery and planetary health. …

DIMERx Awarded Up to $15M by NIDA Under NIH HEAL Initiative® to Advance DMX-101 as a Non-Addictive Oral Therapy for Chronic Pain
SAN FRANCISCO, June 25, 2025 (GLOBE NEWSWIRE) -- DIMERx, Inc., a late-stage biopharmaceutical company entering growth phase, today announced it has been awarded a UG3/UH3 cooperative agreement (UG3DA061645) for up to $15 million from the National Institute …

OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment …

Gero Launches ProtoBind-Diff, a Structure-Free AI Foundation Model for Targeted Small Molecule Discovery
ProtoBind-Diff generates drug-like molecules for specific protein targets using only their amino acid sequences—no 3D structures required. The model performs competitively with leading structure-based tools in predicting binding strength, while also …

BioCardia Announces New United States Patent for Helix Biotherapeutic Delivery System
SUNNYVALE, Calif., June 25, 2025 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announces that the United States Patent Office …

ImmuCell Embarks on CEO Succession Planning Process
PORTLAND, Maine, June 25, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the …

OPKO Health and Entera Bio Abstract for First-in-Class Dual GLP-1/Glucagon Tablet Candidate for Patients with Obesity and Metabolic Disorders Selected for Presentation at the ENDO 2025 Annual Meeting
MIAMI and JERUSALEM, June 25, 2025 (GLOBE NEWSWIRE) -- OPKO Health, Inc. (NASDAQ: OPK) and Entera Bio Ltd. (NASDAQ: ENTX) (“Entera”) today announced that new pharmacologic and pharmacokinetic in vivo data for investigational oral OPK-88006 tablet treatment …

HealthLynked Partners with Endlink to Accelerate EMR and Hospital System Integration
NAPLES, Fla., June 25, 2025 (GLOBE NEWSWIRE) -- via IBN -- HealthLynked Corp. (OTCQB: HLYK), a pioneer in healthcare technology and patient engagement, today announced a strategic partnership with Endlink, a healthcare data integration firm led by industry …

Ovid Therapeutics Enters Agreement with Immedica Pharma AB for Sale of Future Ganaxolone Royalties
NEW YORK and STOCKHOLM, Sweden, June 25, 2025 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (Nasdaq: OVID), a biopharmaceutical company dedicated to developing small molecule medicines for brain conditions with significant unmet need, today announced that it …

ZyVersa Therapeutics Announces Share Purchase Agreement for up to $10 Million in Partnership with Williamsburg Venture Holdings to Fund Clinical Development of Cholesterol Efflux Mediator™ VAR 200
WESTON, Fla., June 25, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (Nasdaq: ZVSA; “ZyVersa”), a clinical stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who …

Clearmind Medicine Enrolls First Patient in its Clinical Trial for Alcoholism Treatment
CMND-100 has the potential to provide an innovative and advanced treatment option for hundreds of millions of people around the world afflicted with Alcohol Use Disorder Vancouver, Canada, June 25, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: …

Biogen to Advance Investigational Spinal Muscular Atrophy Asset to Registrational Studies Based on Positive Interim Phase 1 Results
Salanersen (BIIB115/ION306) is a novel antisense oligonucleotide (ASO) with the potential to achieve high efficacy and once yearly dosing in spinal muscular atrophy (SMA) Interim Phase 1 data show children with SMA previously treated with gene therapy …

Cognition Therapeutics Provides Regulatory Update on Zervimesine (CT1812) in Alzheimer’s Disease and Dementia with Lewy Bodies (DLB)
- End-of-Phase 2 Meeting with FDA for Mild-to-Moderate Alzheimer’s Disease Scheduled - - Applications for IND and Breakthrough Status Filed for Dementia with Lewy Bodies - PURCHASE, N.Y., June 25, 2025 (GLOBE NEWSWIRE) -- Cognition Therapeutics, Inc., (the …

Verano Unveils Bodega-Style Dispensary Experience at Zen Leaf Cave Creek in Phoenix
Flipping the script on the traditional dispensary format, the new bodega-style shopping experience offers customers the freedom to browse and select their favorite items directly from shelves featuring one of the largest assortments of directly accessible …

Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer
Phase 1/2a clinical trial currently supported by a $3.0 million grant from the U.S. Department of Defense Trial will enroll children with high grade glioma and ependymoma HOUSTON, June 25, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) ( …

Arbutus Reacquires Greater China Rights to Imdusiran and Announces Scientific Advisory Board with Late-Stage Clinical Focus
Qilu Pharmaceutical and Arbutus mutually agree to conclude strategic partnership for imdusiran in Greater China Drs. Jordan Feld, Ed Gane, Anna Lok, Mark Sulkowski and Man-Fung Yuen join Arbutus Scientific Advisory Board WARMINSTER, Pa., June 25, 2025 ( …